Standard BioTools
LAB
131 hedge funds and large institutions have $855M invested in Standard BioTools in 2019 Q1 according to their latest regulatory filings, with 47 funds opening new positions, 60 increasing their positions, 17 reducing their positions, and 15 closing their positions.
655% more call options, than puts
Call options by funds: $302K | Put options by funds: $40K
253% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 17
213% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 15
101% more capital invested
Capital invested by funds: $426M → $855M (+$429M)
32% more funds holding
Funds holding: 99 → 131 (+32)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
8.26% less ownership
Funds ownership: 101.5% → 93.24% (-8.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$19.2M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$15.2M |
| 3 |
RI
RTW Investments
New York
|
+$11M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$10.8M |
| 5 |
Renaissance Technologies
New York
|
+$9.64M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCS
Levin Capital Strategies
New York
|
-$98.9M |
| 2 |
HVC
Healthcare Value Capital
Woodcliff Lake,
New Jersey
|
-$3.88M |
| 3 |
ICM
Indaba Capital Management
San Francisco,
California
|
-$3.45M |
| 4 |
PVI
Pura Vida Investments
New York
|
-$2.73M |
| 5 |
Neuberger Berman Group
New York
|
-$2.64M |
LAB Hedge Fund Activity: Q1 2019 in Review
131 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q1 2019, worth a combined $855M — up 101% from $426M a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new LAB positions and 15 closed out — a net gain of 32 holders — while 60 added to existing stakes and 17 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $19.2M. The largest seller was Levin Capital Strategies, cutting an estimated $98.9M.
- 131 institutional investors held Standard BioTools (LAB) as of Q1 2019, up from 99 in Q4 2018.
- Funds reported $855M of Standard BioTools stock for Q1 2019, up 101% quarter-over-quarter.
- 47 funds opened new Standard BioTools positions in Q1 2019 and 15 closed out, a net change of +32 holders.
- The largest Standard BioTools buyer in Q1 2019 was Fidelity Investments, an estimated $19.2M added.
- The largest Standard BioTools seller in Q1 2019 was Levin Capital Strategies, an estimated $98.9M sold.
Based on aggregated 13F filings for Q1 2019.